103 related articles for article (PubMed ID: 34407179)
1. Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies.
Zuckerman AD; DeClercq J; Choi L; Cowgill N; McCarthy K; Lounsbery B; Shah R; Kehasse A; Thomas KC; Sokos L; Stutsky M; Young J; Carter J; Lach M; Wise K; Thomas TT; Ortega M; Lee J; Lewis K; Dura J; Gazda NP; Gerzenshtein L; Canfield S
Am J Health Syst Pharm; 2021 Nov; 78(23):2142-2150. PubMed ID: 34407179
[TBL] [Abstract][Full Text] [Related]
2. Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.
Academia EC; Mejías-De Jesús CM; Stevens JS; Jia LY; Yankama T; Patel C; Lee J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1438-1446. PubMed ID: 34595953
[No Abstract] [Full Text] [Related]
3. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid arthritis medication adherence in a health system specialty pharmacy.
Berger N; Peter M; DeClercq J; Choi L; Zuckerman AD
Am J Manag Care; 2020 Dec; 26(12):e380-e387. PubMed ID: 33315331
[TBL] [Abstract][Full Text] [Related]
5. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy.
Peter ME; Zuckerman AD; DeClercq J; Choi L; James C; Cooper K; Choi J; Nadler M; Tanner SB
J Manag Care Spec Pharm; 2021 Jul; 27(7):882-890. PubMed ID: 34185565
[No Abstract] [Full Text] [Related]
6. Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies.
Zuckerman A; Crumb J; Kandah HM; Platt T; Duckworth D; Lo K; Mitchell D; Diamantides E; Streck CM; DeClercq J; Choi L; Patel R
J Manag Care Spec Pharm; 2023 Jul; 29(7):740-748. PubMed ID: 37404071
[No Abstract] [Full Text] [Related]
7. Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy.
Petry L; Zuckerman AD; DeClercq J; Choi L; Lynch B; Saknini M
J Manag Care Spec Pharm; 2023 Jul; 29(7):732-739. PubMed ID: 37404072
[No Abstract] [Full Text] [Related]
8. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence.
Stockl KM; Shin JS; Lew HC; Zakharyan A; Harada AS; Solow BK; Curtis BS
J Manag Care Pharm; 2010 Oct; 16(8):593-604. PubMed ID: 20866164
[TBL] [Abstract][Full Text] [Related]
9. Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Bourret J; Koenig A
J Manag Care Spec Pharm; 2016 Mar; 22(3):209-18. PubMed ID: 27003550
[TBL] [Abstract][Full Text] [Related]
10. Closing the Gap: Identifying Rates and Reasons for Nonadherence in a Specialty Population.
Paolella D; Cherry E; Jolly JA; DeClercq J; Choi L; Zuckerman A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1282-1288. PubMed ID: 31663457
[TBL] [Abstract][Full Text] [Related]
11. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
Aaltonen KJ; Turunen JH; Sokka T; Puolakka K; Valleala H
Clin Exp Rheumatol; 2016; 34(4):694-7. PubMed ID: 27213997
[TBL] [Abstract][Full Text] [Related]
12. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
13. Assessment of long-term medication adherence with cystic fibrosis: An integrated approach.
Platt T; Kormelink LN; Autry EB; Rossoll SJ; Kuhn RJ
Pediatr Pulmonol; 2024 Feb; 59(2):458-464. PubMed ID: 38018665
[TBL] [Abstract][Full Text] [Related]
14. Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies.
McCabe CC; Barbee MS; Watson ML; Billmeyer A; Lee CE; Rupji M; Chen Z; Haumschild R; El-Rayes B
Am J Health Syst Pharm; 2020 Jul; 77(14):1118-1127. PubMed ID: 32537656
[TBL] [Abstract][Full Text] [Related]
15. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
[TBL] [Abstract][Full Text] [Related]
16. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
[TBL] [Abstract][Full Text] [Related]
17. Self-reported adherence and reasons for nonadherence among patients with low proportion of days covered for antihypertension medications.
Kharmats AY; Martinez TR; Belli H; Zhao Y; Mann DM; Schoenthaler AM; Voils CI; Blecker S
J Manag Care Spec Pharm; 2023 May; 29(5):557-563. PubMed ID: 37121253
[No Abstract] [Full Text] [Related]
18. Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients.
Chu LH; Kawatkar AA; Gabriel SE
Clin Ther; 2015 Mar; 37(3):660-666.e8. PubMed ID: 25618317
[TBL] [Abstract][Full Text] [Related]
19. Navigating the Wild West of Medication Adherence Reporting in Specialty Pharmacy.
Canfield SL; Zuckerman A; Anguiano RH; Jolly JA; DeClercq J; Wascher M; Choi L; Knox S; Mitchell DG
J Manag Care Spec Pharm; 2019 Oct; 25(10):1073-1077. PubMed ID: 31556829
[TBL] [Abstract][Full Text] [Related]
20. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
